Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Critical Role of Molecular-Based Stratification in Low-Risk Myelodysplastic Syndrome with Direct Progression to Acute Myeloid Leukemia: A Case Report.

International journal of molecular sciences·2026
Same author

Physico-Chemical and Biological Evaluation of Spin-Coated Chromium-Doped Hydroxyapatite in Dextran Matrix Coatings.

Biomimetics (Basel, Switzerland)·2026
Same author

Differential Plasma Expression of sTNF-R, TNF-α, PDGF-AA, IL-17A, and IL-1β Across the Colorectal Neoplasia Spectrum.

Biomolecules·2026
Same author

COL10A1 Overexpression Promotes Gastric Cancer Aggressiveness Through EMT and Major Oncogenic Pathways.

International journal of molecular sciences·2025
Same author

Serum Behavior of NT-3 and VEGFβ, Two Unstudied Growth Factors in Patients with Diabetes Mellitus and End-Stage Renal Disease.

Journal of clinical medicine·2025
Same author

Long Non-Coding RNAs: Significant Drivers of Carcinogenesis Mechanisms in Head and Neck Squamous Cell Carcinoma.

Current issues in molecular biology·2025

Related Experiment Video

Updated: Sep 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

548

Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy.

Laura Denisa Dragu1, Mihaela Chivu-Economescu1, Ioana Madalina Pitica1

  • 1Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.

Current Issues in Molecular Biology
|July 29, 2025
PubMed
Summary

Exosomal PD-L1 (ExoPD-L1) drives cancer immune suppression and therapy resistance. Targeting ExoPD-L1 offers a novel strategy to enhance immunotherapy effectiveness by blocking immune escape.

Keywords:
ExoPD-L1cancer immunotherapyexosomeimmune evasiontherapy resistance

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K

Related Experiment Videos

Last Updated: Sep 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

548
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Exosomal PD-L1 (ExoPD-L1) is a key mediator of tumor immune evasion.
  • ExoPD-L1 contributes to systemic immunosuppression beyond the tumor microenvironment (TME).
  • It impacts patient outcomes by modulating immune responses.

Purpose of the Study:

  • To review the mechanisms of ExoPD-L1 in immune suppression and tumor progression.
  • To explore therapeutic strategies targeting ExoPD-L1 for enhanced immunotherapy.
  • To discuss the potential of blocking ExoPD-L1 to overcome cancer immune escape.

Main Methods:

  • Review of literature on exosomal PD-L1.
  • Analysis of mechanisms of ExoPD-L1 interaction with T cell receptors.
  • Exploration of therapeutic strategies including exosome biogenesis inhibitors, antibody neutralization, and RNA interference.

Main Results:

  • ExoPD-L1 facilitates tumor immune evasion and systemic immunosuppression.
  • Targeting ExoPD-L1 presents a novel approach to counteract cancer immune escape.
  • Combination therapies involving ExoPD-L1 blockade show potential to improve immunotherapy efficacy.

Conclusions:

  • ExoPD-L1 plays a critical role in cancer progression and therapy resistance.
  • Targeting ExoPD-L1 is a promising strategy to enhance cancer immunotherapy.
  • Further research is needed to optimize clinical application and minimize off-target effects.